(696 days)
Not Found
No
The summary describes a device that uses electromagnetic energy for heating tissue and mentions no AI/ML components or functionalities.
Yes
The device is indicated to "generate deep heat within body tissues for treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures," which is a clear therapeutic purpose.
No
The device is indicated for treatment (generating deep heat for pain relief, muscle spasms, and joint contractures) rather than diagnosing conditions.
No
The device description explicitly details a "hand piece tip comprised of a coil shaped antenna" and describes the generation of "electromagnetic energy" and "eddy currents," indicating a physical hardware component responsible for the therapeutic effect. This is not a software-only device.
Based on the provided information, the Biofusionary Bebe System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly states that the device is used to "generate deep heat within body tissues for treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures." This describes a therapeutic function performed directly on the patient's body.
- Device Description: The description explains how the device works by directing electromagnetic energy into tissue to cause heating. This is a physical interaction with the body, not an analysis of samples taken from the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), performing tests on these samples, or providing diagnostic information based on such analysis.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The Biofusionary Bebe System does not fit this description. It is a therapeutic device.
N/A
Intended Use / Indications for Use
The Biofusionary Bebe System is indicated to be used to generate deep heat within body tissues for treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.
The Biofusionary Bebe System is indicated to be used to generate deep heat within body tissues for the treatment of niedical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.
Product codes
IMJ
Device Description
The Biofusionary Bebe is used for diathermic heating of tissue. The Biofusionary Bebe hand piece tip is comprised of a coil shaped antenna which directs the flow of current parallel to the tissue surface, without contacting the tissue surface, thereby directing the magnetic component of the electromagnetic energy into tissue to result in the formation of eddy currents in tissue. These eddy currents encounter resistance, leading to localized heating.
The Biofusionary Bebe is comprised of the following main components: Main console containing the major electrical components including:
- Radiofrequency (RF) generator .
- Control module .
- Footswitch .
- Recirculating chiller .
- Isolation transformer .
- Connection ports for hand piece, footswitch and power cord .
Hand piece incorporating: - Treatment tip .
- Umbilical connection to main console. .
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Body tissues
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Product testing was conducted to evaluate conformance to product specification. The results showed the system met specification.
Additionally, the product passed numerous bench studies where heating capabilities were evaluated; these include bench top studies on tissue phantoms and samples of ex vivo porcine skin tissue, in vivo studies on rats and two clinical studies completed to further determine feasibility and safety and effectiveness.
In heating characterization studies, phantoms were used to mimic treatment sites. A heating treatment protocol described in the User Manual resulted in reaching a therapeutic level of 40 °C in approximately 5 minutes at the surface. · A temperature of 40 °C was reached within 5 to 10 minutes at 1cm and within 8 to 13 minutes at 2 cm. The surface of the phantom did not exceed 45 ℃ for the duration of the study.
A usability study was conducted in which naive users were first instructed to review the User Manual and protocols for use of the device, followed by actual use of the device in a mock setting. The users were questioned and observed. The results of the study indicated that the instructions were adequate. The users understood the instructions and could apply the device according to the instructions.
Occupational testing for safe levels of exposure to electromagnetic energy was performed in accordance with the safety standard IEEE 95.1-2005.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 890.5290 Shortwave diathermy.
(a)
Shortwave diathermy for use in applying therapeutic deep heat for selected medical conditions —(1)Identification. A shortwave diathermy for use in applying therapeutic deep heat for selected medical conditions is a device that applies to specific areas of the body electromagnetic energy in the radiofrequency (RF) bands of 13.56 megahertz (MHz) or 27.12 MHz and that is intended to generate deep heat within body tissues for the treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.(2)
Classification. Class II (performance standards).(b)
Nonthermal shortwave therapy —(1)Identification. A nonthermal shortwave therapy is a prescription device that applies to the body pulsed electromagnetic energy in the RF bands of 13.56 MHz or 27.12 MHz and that is intended for adjunctive use in the palliative treatment of postoperative pain and edema of soft tissue by means other than the generation of deep heat within body tissues as described in paragraph (a) of this section.(2)
Classification: Class II (special controls). The device is classified as class II. The special controls for this device are:(i) Components of the device that come into human contact must be demonstrated to be biocompatible.
(ii) Appropriate analysis/testing must demonstrate that the device is electrically safe and electromagnetically compatible in its intended use environment.
(iii) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Non-clinical performance testing must characterize the output waveform of the device and demonstrate that the device meets appropriate output performance specifications. The output characteristics and the methods used to determine these characteristics, including the following, must be determined:
(A) Peak output power;
(B) Pulse width;
(C) Pulse frequency;
(D) Duty cycle;
(E) Characteristics of other types of modulation that may be used;
(F) Average measured output powered into the RF antenna/applicator;
(G) Specific absorption rates in saline gel test load or other appropriate model;
(H) Characterization of the electrical and magnetic fields in saline gel test load or other appropriate model for each RF antenna and prescribed RF antenna orientation/position; and
(I) Characterization of the deposited energy density in saline gel test load or other appropriate model.
(iv) A detailed summary of the clinical testing pertinent to use of the device to demonstrate the effectiveness of the device in its intended use.
(v) Labeling must include the following:
(A) Output characteristics of the device;
(B) Recommended treatment regimes, including duration of use; and
(C) A detailed summary of the clinical testing pertinent to the use of the device and a summary of the adverse events and complications.
(vi) Nonthermal shortwave therapy devices marketed prior to the effective date of this reclassification must submit an amendment to their previously cleared premarket notification (510(k)) demonstrating compliance with these special controls.
0
MAR 1 0 2014
Section 5: 510(k) Summary
K121123 510(k)#
General Information
| Classification | Class II |
|---|---|
| Trade Name | Biofusionary Bebe™ System |
| Product Code: | IMJ |
| Regulation Number: | 21 CFR 890.5290 |
| Common Name: | Shortwave Diathermy |
| Submitter | Rocky Mountain Biosystems, Inc |
| 3930 Youngfield Street | |
| Wheat Ridge, CO 80033 | |
| Tel: (303)277-1140 | |
| Fax: (303)277-1150 | |
| Contact | Kevin Marchitto, Ph.D. |
| Date: | March 5, 2014 |
Intended Use
The Biofusionary Bebe System is indicated to be used to generate deep heat within body tissues for treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.
Predicate Device(s)
Chattanooga Group-Intelect SWD 100, K083433
Device Description
The Biofusionary Bebe is used for diathermic heating of tissue. The Biofusionary Bebe hand piece tip is comprised of a coil shaped antenna which directs the flow of current parallel to the tissue surface, without contacting the tissue surface, thereby directing the magnetic component of the electromagnetic energy into tissue to result in the formation of eddy currents in tissue. These eddy currents encounter resistance, leading to localized heating.
Materials
The Biofusionary Bebe is comprised of the following main components: Main console containing the major electrical components including:
- Radiofrequency (RF) generator .
- Control module .
1
- Footswitch .
- Recirculating chiller .
- Isolation transformer .
- Connection ports for hand piece, footswitch and power cord .
Hand piece incorporating:
- Treatment tip .
- Umbilical connection to main console. .
All materials used in the manufacture of the Biofusionary Bebe are suitable for this use and have been used in numerous, previously cleared products.
Testing
Product testing was conducted to evaluate conformance to product specification. The results showed the system met specification.
Additionally, the product passed numerous bench studies where heating capabilities were evaluated; these include bench top studies on tissue phantoms and samples of ex vivo porcine skin tissue, in vivo studies on rats and two clinical studies completed to further determine feasibility and safety and effectiveness.
In heating characterization studies, phantoms were used to mimic treatment sites. A heating treatment protocol described in the User Manual resulted in reaching a therapeutic level of 40 °C in approximately 5 minutes at the surface. · A temperature of 40 °C was reached within 5 to 10 minutes at 1cm and within 8 to 13 minutes at 2 cm. The surface of the phantom did not exceed 45 ℃ for the duration of the study.
A usability study was conducted in which naive users were first instructed to review the User Manual and protocols for use of the device, followed by actual use of the device in a mock setting. The users were questioned and observed. The results of the study indicated that the instructions were adequate. The users understood the instructions and could apply the device according to the instructions.
Occupational testing for safe levels of exposure to electromagnetic energy was performed in accordance with the safety standard IEEE 95.1-2005.
| # | Standards # | Standards
Organization | Standards Title | Version | date |
|----|-----------------------------------------------------------------------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-----------|
| 1 | 13485 | ISO | Medical Devices - Quality
Management Systems -
Requirements for regulatory
purposes | 2003 | 1/16/2012 |
| 2 | 14971 | ISO | Medical Devices - Risk Management
- Part 1: Application of risk analysis | 2007 | 1/16/2012 |
| 3 | 10993-1 | ISO | Biological Evaluation of Medical
Devices - Part 1 - Evaluation and
Testing | 2009 | 1/16/2012 |
| 4 | EN 60601-1 (1990)
+A1 (1993)
+A2 (1995)
+A12 (1993)
+A13 (1996) | IEC | Medical electrical equipment -
General requirements for safety | 60601-1
(1990)
+A1 (1993)
+A2 (1995)
+A12 (1993) | 1/16/2012 |
| | +Corrigenda (July
-
| | | +A13 (1996)
+Corrigenda
(July 1994) | |
| 5 | EN 60601-2-3 | IEC | *Medical electrical equipment - Part
2: Particular requirements for the
safety of short-wave therapy
equipment | 1993 | 1/16/2012 |
| 6 | EN 55011 (2009)
+A1 (2010) | IEC | Industrial, scientific and medical
equipment, Radio-frequency
disturbance characteristics. Limits
and methods of measurement | EN 55011
(2009)
+A1 (2010) | 1/16/2012 |
| 7 | IEC 60601-1-2 | IEC | Essential Performance, Risk Analysis
and Immunity Testing | 3rd ed. (2007-
03) | 1/16/2012 |
| 8 | CISPR 16-1 | CISPR | Specification for radio disturbance
and immunity measurement
apparatus and methods - Part 1:
Radio disturbance and immunity
measuring apparatus | Ed. 2.1 (2002-
10) | 1/16/2012 |
| 9 | CISPR 11 | CISPR | Industrial, scientific and medical
(ISM) radio-frequency equipment -
Electromagnetic disturbance
characteristics - Limits and methods
of measurement. | Ed. 5.0 (2009-
05) | 1/16/2012 |
| 10 | CISPR 16-2 | CISPR | Specification for radio disturbance
and immunity measurement
apparatus and methods - Part 2:
Methods of measurement of
disturbances and immunity | Ed/ 2.0 (2003-
07) | 1/16/2012 |
| 11 | CISPR 16-3 | CISPR | Specification for radio disturbance
and immunity measurement
apparatus and methods - Part 3:
Reports and recommendations of
CISPR | Ed. 1.1 (2002-
08) | 1/16/2012 |
| 12 | CISPR 16-4 | CISPR | Part 4-1: Uncertainties, statistics and
limit modeling - Uncertainties in
standardized EMC tests | Ed. 1.0 (2002-
05) | 1/16/2012 |
| 13 | EN 61000-3-3 | IEC | Limits - Limitation of voltage
changes. voltage fluctuations and
flicker in public low-voltage supply
systems, for equipment with rated
current ≤ 16 A per phase and not
subject to conditional connection. | 2008 | 1/16/2012 |
| 14 | EN 61000-3-2
+A1 (2009)
- A2 (2009) | IEC | Electromagnetic compatibility
(EMC) - Part 3-2 - Limits - Limits
for harmonic current emissions
(equipment input current ≤ 16 A per
phase) | 2006
+A1 (2009) - A2 (2009) | 1/16/2012 |
| 15 | EN 60601-1-4 | IEC | Collateral Standard - Programmable
electronic systems | 2000 | 1/16/2012 |
| 16 | IEEE C95.1 | IEEE | Safety Levels with Respect to
Human Exposure to Radiofrequency
Electromagnetic Fields, 3 kHz to 300
GHz. | 2005 | 1/16/2012 |
The Biofusionary Bebe complies with the following performance standards:
2
- The 60601-2-3 standard is not recognized by the FDA
3
Summary of Substantial Equivalence
The Rocky Mountain Biosystems, Inc, Biofusionary Bebe™ is equivalent to the predicate product. The indications for use, basic overall function, methods of manufacturing, and materials used are substantially equivalent. The results of heating studies also support the substantial equivalence of the Biofusionary Bebe with the predicate device.
Technological Characteristics
The predicate product, the Chatanooga Intelect, is supplied with two different electrodes: the Monode (Drum) Electrode is an induction coil for treatment of mid-sized areas. The Diplode is a capacitive coupled set of electrodes for treatment of large areas and for treatment of suitable body parts that can be warmed from three sides at the same time. The device may be operated in pulsed or continuous mode.
The drum electrode, an induction coil, has a 14 cm diameter. It is fixed in size and attached to a boom that allows it to be positioned at a single location on the patient. The fixed nature of the electrode allows the operator to provide hands-free treatment of a 14 cm diameter area of the skin.
The operation of the Biofusionary Bebe device is most similar to the use of the Intelect Monode Electrode used in continuous mode
The Biofusionary Bebe device has a hand piece with 3 cm diameter tip. The device operates in continuous mode at 170W. The device allows the operator to treat a 12 cm diameter area by choosing timer settings and protocols. Hands-free operation is not possible.
Power delivery
Both devices operate at 27.1 MHz.
The Intelect allows for operation in a pulsed mode (200 W) with a variable duty cycle, or a continuous mode (100 W) with variable power settings. The Biofusionary Bebe operates in a fixed continuous mode at 170W.
The operation of the Biofusionary Bebe device is most similar to the use of the Intelect Monode used in continuous mode operation.
Applicator
The Intelect is supplied with a drum electrode, the induction coil, which has a 14 cm diameter. It is fixed in size and attached to a boom that allows it to be positioned at a single location on the patient. The fixed nature of the electrode allows the operator to provide hands-free treatment of a 14 cm diameter area of the skin.
The Biofusionary Bebe device has a hand piece with 3 cm diameter tip. The device allows the operator to treat a 12 cm diameter area by choosing timer settings and protocols. Hands-free operation is not possible.
4
Heating Capabilities
Two different electrode configurations are available for the Intelect. The Monode (Drum) Electrode is an induction coil for treatment of mid-sized areas. The Diplode is a capacitive coupled set of electrodes for treatment of large areas and for treatment of suitable body parts that can be warmed from three sides at the same time.
The devices manage deep or shallow heating capabilities in similar manner:
Both devices heat to therapeutic temperatures for a minimum of 1 minute, and the maximum recommended treatment time is 30 minutes. Both devices provide therapeutic heating for the duration of the treatment cycle, once the therapeutic temperature is reached.
Both devices provide instructions and warnings for variable depth heating.
The Intelect User Manual directs: "The Electrode-Skin Distance (ESD) must be small for surface warming and large for depth warming. A larger Electrode-Skin Distance (ESD) is necessary for patients with a thick layer of subcutaneous fat in order to achieve the necessary warming of deep-lying tissue."
The Biofusionary Bebe provides protocols in the User Manual that aid the operator in applying heat to the tissues appropriately.
Safety Precautions:
Patient treatment criteria and warnings are provided in the User Manuals of both the Intelect and Biofusionary Bebe to assure safe and effective treatment:
The Intelect manual recommends four different dosage levels for operation using patient feedback to accommodate patients with different pain sensation levels, the lowest level being used for those who cannot sense pain.
The Biofusionary Bebe requires user feedback to determine the appropriate conditions of treatment. The User Manual provides warnings and protocols to address patients with little or no sensation of pain.
Both devices rely on patient feedback to avoid the risk of excessive warming, and both devices provide similar warnings, cautions and contraindications in their User Manuals.
5
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - W(166-G609 Silver Spring, MD 20993-0002
March 10, 2014
Rocky Mountain Biosystems, Inc. c/o Kevin Marchitto President 3930 Youngfield Street Wheat Ridge. CO 80033
K121123 Re:
Trade Name: Biofusionary Bebe™M System · Regulation Number: 21 CFR 890.5290 Regulation Name: Shortwave Diathermy Regulatory Class: Class II Product Code: IMJ Dated: January 6, 2014 Received: January 8, 2014
Dear Mr. Marchitto:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into cither class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that I'DA 's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
6
Page 2 of 3 - Mr. Kevin Marchitto
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Joyce M. Whang -S
for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement on last page.
510(k) Number (if known) K121123
Device Name Biofusionary Bebe System
Indications for Use (Describe)
The Biofusionary Bebe System is indicated to be used to generate deep heat within body tissues for the treatment of nedical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
FORM FDA 3881 (1/14)
PSC Publishing Services (301) 443-6740 단
8
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."